ACLARION INC

NASDAQ: ACONW (Aclarion Inc)

Last update: 16 hours ago

0.029

0.01 (35.51%)

Previous Close 0.021
Volume 70,421
52 Weeks Range
0.024 (-18%) — 0.029 (0%)
Operating Margin (TTM) -10,789.22%
Diluted EPS (TTM) -6.58
Quarterly Revenue Growth (YOY) 78.10%
Total Debt/Equity (MRQ) 47.32%
Current Ratio (MRQ) 14.17
Operating Cash Flow (TTM) -8.95 M
Levered Free Cash Flow (TTM) -5.60 M
Return on Assets (TTM) -45.78%
Return on Equity (TTM) -74.07%

AIStockmoo Score

-0.4
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Return on Capital info NA
Earnings Trend info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
From our AI technical analysis of the chart. info NA
Trend Strength info NA
Technical Setup info NA
Candle Patterns info NA
Medium-Term Trend info NA
No recent price targets, so based on how targets have been revised. info
Holdings' Sentiment info NA
News Mood info NA
Short interest +16.8% from 31 Aug to 30 Oct 2026, 7.1 days to cover (FINRA). info
Insider Activity info NA
Institutional Flow info NA
Market environment cautious. info
Sector outperforming the market.
Only one pillar has a clear reading, so the score is unchanged.
Price Volatility info NA
No clear trend across the short, medium and long term. info
No clear signal from support and resistance. info
Final Score -0.39
Show all

Market Trend

Short Term Medium Term
Industry Health Information Services (US) Mixed Bearish
Health Information Services (Global) Mixed Bearish
Stock Aclarion Inc - -

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
ACONW - - - - -0.4
CARL 477 M - - 6.29 1.6
SY 166 M - - 0.770 -2.9
OTRKP - - - - -2.9
TEM 10 B - - 19.68 -0.1
HQY 8 B - 34.21 4.05 0.0

Select this tab to load the latest available analysis.

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in Broomfield, Colorado.

Sector Healthcare
Industry Health Information Services

Ownership

Name Date Shares Held
Captrust Financial Advisors 30 Sep 2026 63,400

No data within this time range.

Institutions

Short Interest

Settlement Shares Days to cover
30 Oct 2026 81,593 7.1
15 Oct 2026 73,843 4.2
30 Sep 2026 67,490 5.6
15 Sep 2026 66,327 27.1
31 Aug 2026 69,875 8.3
14 Aug 2026 231,797 4.2

FINRA short interest via Nasdaq, reported twice a month.

Date Type Details
28 Oct 2026 Yahoo Finance Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of +61.91% and +0.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
27 Oct 2026 Yahoo Finance HCA Healthcare (HCA) Q3 Earnings and Revenues Top Estimates
HCA (HCA) delivered earnings and revenue surprises of +7.12% and +2.50%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
22 Oct 2026 Yahoo Finance Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs
Study conducted at London Spine Clinic found Nociscan's noninvasive scan successfully identified painful discs, agreeing with discography, the invasive gold standard, in up to 87% of casesNociscan also spared patients the needles, added cost, and recovery time that is often associated with…
20 Oct 2026 Yahoo Finance Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026
85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable alternative to provocative discographyCLARITY trial expanded to eleven clinical sites…
13 Oct 2026 Yahoo Finance Aclarion to Present at the 20th Annual LD Micro Main Event
BROOMFIELD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion (NASDAQ: ACON) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Aclarion is scheduled to present on Tuesday…
08 Oct 2026 Yahoo Finance Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment paceInitial readout timing to be updated by year-end based on demonstrated Q4 enrollment increasesOverall trial duration remains on track BROOMFIELD, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE)…
29 Sep 2026 Yahoo Finance Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical researchCLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical…

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria